S100A16 stabilizes the ITGA3‑mediated ECM‑receptor interaction pathway to drive the malignant properties of lung adenocarcinoma cells via binding MOV10

Yang,Lianren; Shen,Ajuan; Wang,Rujun; Zheng,Zhihui

doi:10.3892/mmr.2024.13376

S100A16 stabilizes the ITGA3‑mediated ECM‑receptor interaction pathway to drive the malignant properties of lung adenocarcinoma cells via binding MOV10

Authors:
- Lianren Yang
- Ajuan Shen
- Rujun Wang
- Zhihui Zheng
View Affiliations

Affiliations: Department of Medical Oncology, Taihe County People's Hospital, Fuyang, Anhui 236600, P.R. China
Published online on: October 23, 2024 https://doi.org/10.3892/mmr.2024.13376
Article Number: 11
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung adenocarcinoma (LUAD) is highly associated with lung cancer‑associated mortality. Notably, S100 calcium‑binding protein A16 (S100A16) has been increasingly considered to have prognostic value in LUAD; however, the underlying mechanism remains unknown. In the present study, S100A16 expression levels in LUAD tissues and cells were respectively analyzed by the UALCAN database and western blotting. Cell Counting Kit‑8 and 5‑ethynyl‑2'‑deoxyuridine assays were used to examine cell proliferation, whereas wound healing, Transwell and tube formation assays were used to assess cell migration, invasion and angiogenesis, respectively. Western blotting was also used to examine the expression levels of proteins associated with metastasis, angiogenesis, focal adhesion and the extracellular matrix (ECM)‑receptor interaction pathways. The relationship between S100A16 and Mov10 RNA helicase (MOV10) was predicted by bioinformatics tools, and was verified using a co‑immunoprecipitation assay. Furthermore, the interaction between MOV10 and integrin α3 (ITGA3) was verified by RNA immunoprecipitation assay, and the actinomycin D assay was used to detect ITGA3 mRNA stability. The results demonstrated that S100A16 expression was increased in LUAD tissues and cell lines, and was associated with unfavorable outcomes. Knocking down S100A16 expression hindered the proliferation, migration, invasion and angiogenesis of LUAD cells. Furthermore, S100A16 was shown to bind to MOV10 and positively modulate MOV10 expression in LUAD cells, while MOV10 overexpression partially reversed the suppressive role of S100A16 knockdown on the aggressive phenotypes of LUAD cells. Furthermore, it was demonstrated that S100A16 regulated the stability of ITGA3 mRNA via MOV10 to mediate ECM‑receptor interactions. In conclusion, S100A16 may bind to MOV10 to stabilize ITGA3 mRNA and regulate ECM‑receptor interactions, hence contributing to the malignant progression of LUAD.

View Figures

View References

1	Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A and Bray F: Cancer statistics for the year 2020: An overview. Int J Cancer. Apr 5–2021.(Epub ahead of print). View Article : Google Scholar
2	Cao M and Chen W: Epidemiology of lung cancer in China. Thorac Cancer. 10:3–7. 2019. View Article : Google Scholar : PubMed/NCBI
3	Skřičková J, Kadlec B, Venclíček O and Merta Z: Lung cancer. Cas Lek Cesk. 157:226–236. 2018.PubMed/NCBI
4	Myers DJ and Wallen JM: Lung adenocarcinoma. StatPearls. StatPearls Publishing; Treasure Island, FL: 2023
5	Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T and Dive C: Progress and prospects of early detection in lung cancer. Open Biol. 7:1700702017. View Article : Google Scholar : PubMed/NCBI
6	Huang P, Zhu S, Liang X, Zhang Q, Liu C and Song L: Revisiting lung cancer metastasis: Insight from the functions of long non-coding RNAs. Technol Cancer Res Treat. 20:153303382110384882021. View Article : Google Scholar : PubMed/NCBI
7	Slim A, Kamoun H, Hadidene Y, Smadhi H, Meddeb A and Megdiche ML: Postoperative recurrence of primary lung cancer: Anatomo-clinical and therapeutic study. Tunis Med. 99:560–568. 2021.PubMed/NCBI
8	Bresnick AR, Weber DJ and Zimmer DB: S100 proteins in cancer. Nat Rev Cancer. 15:96–109. 2015. View Article : Google Scholar : PubMed/NCBI
9	Basnet S, Vallenari EM, Maharjan U, Sharma S, Schreurs O and Sapkota D: An update on S100A16 in human cancer. Biomolecules. 13:10702023. View Article : Google Scholar : PubMed/NCBI
10	Sun X, Wang T, Zhang C, Ning K, Guan ZR, Chen SX, Hong TT and Hua D: S100A16 is a prognostic marker for colorectal cancer. J Surg Oncol. 117:275–283. 2018. View Article : Google Scholar : PubMed/NCBI
11	Saito K, Kobayashi M, Nagashio R, Ryuge S, Katono K, Nakashima H, Tsuchiya B, Jiang SX, Saegusa M, Satoh Y, et al: S100A16 is a prognostic marker for lung adenocarcinomas. Asian Pac J Cancer Prev. 16:7039–7044. 2015. View Article : Google Scholar : PubMed/NCBI
12	Katono K, Sato Y, Kobayashi M, Nagashio R, Ryuge S, Igawa S, Ichinoe M, Murakumo Y, Saegusa M and Masuda N: S100A16, a promising candidate as a prognostic marker for platinum-based adjuvant chemotherapy in resected lung adenocarcinoma. Onco Targets Ther. 10:5273–5279. 2017. View Article : Google Scholar : PubMed/NCBI
13	Wu C, Yang J, Lin X, Li R and Wu J: miR-508-5p serves as an anti-oncogene by targeting S100A16 to regulate AKT signaling and epithelial-mesenchymal transition process in lung adenocarcinoma cells. Am J Med Sci. 365:520–531. 2023. View Article : Google Scholar : PubMed/NCBI
14	Nakano M, Kakiuchi Y, Shimada Y, Ohyama M, Ogiwara Y, Sasaki-Higashiyama N, Yano N, Ikeda F, Yamada E, Iwamatsu A, et al: MOV10 as a novel telomerase-associated protein. Biochem Biophys Res Commun. 388:328–332. 2009. View Article : Google Scholar : PubMed/NCBI
15	Mao CG, Jiang SS, Shen C, Long T, Jin H, Tan QY and Deng B: BCAR1 promotes proliferation and cell growth in lung adenocarcinoma via upregulation of POLR2A. Thorac Cancer. 11:3326–3336. 2020. View Article : Google Scholar : PubMed/NCBI
16	Li Q, Ma W, Chen S, Tian EC, Wei S, Fan RR, Wang T, Zhou C and Li T: High integrin α3 expression is associated with poor prognosis in patients with non-small cell lung cancer. Transl Lung Cancer Res. 9:1361–1378. 2020. View Article : Google Scholar : PubMed/NCBI
17	Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and Varambally S: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 19:649–658. 2017. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Recillas-Targa F: Cancer epigenetics: An overview. Arch Med Res. 53:732–740. 2022. View Article : Google Scholar : PubMed/NCBI
20	Kanwal R, Gupta K and Gupta S: Cancer epigenetics: An introduction. Methods Mol Biol. 1238:3–25. 2015. View Article : Google Scholar : PubMed/NCBI
21	Katsumata H, Matsumoto K, Yanagita K, Shimizu Y, Hirano S, Kitajima K, Koguchi D, Ikeda M, Sato Y and Iwamura M: Expression of S100A16 is associated with biological aggressiveness and poor prognosis in patients with bladder cancer who underwent radical cystectomy. Int J Mol Sci. 24:145362023. View Article : Google Scholar : PubMed/NCBI
22	Chen T, Xia DM, Qian C and Liu SR: Integrated analysis identifies S100A16 as a potential prognostic marker for pancreatic cancer. Am J Transl Res. 13:5720–5730. 2021.PubMed/NCBI
23	Chen D, Luo L and Liang C: Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma. PLoS One. 13:e01974022018. View Article : Google Scholar : PubMed/NCBI
24	Fang D, Zhang C, Xu P, Liu Y, Mo X, Sun Q, Abdelatty A, Hu C, Xu H, Zhou G, et al: S100A16 promotes metastasis and progression of pancreatic cancer through FGF19-mediated AKT and ERK1/2 pathways. Cell Biol Toxicol. 37:555–571. 2021. View Article : Google Scholar : PubMed/NCBI
25	Wang N, Wang R, Tang J, Gao J, Fang Z, Zhang M, Shen X, Lu L and Chen Y: Calbindin S100A16 promotes renal cell carcinoma progression and angiogenesis via the VEGF/VEGFR2 signaling pathway. Contrast Media Mol Imaging. 2022:56020112022. View Article : Google Scholar : PubMed/NCBI
26	You X, Li M, Cai H, Zhang W, Hong Y, Gao W, Liu Y, Liang X, Wu T, Chen F and Su D: Calcium binding protein S100A16 expedites proliferation, invasion and epithelial-mesenchymal transition process in gastric cancer. Front Cell Dev Biol. 9:7369292021. View Article : Google Scholar : PubMed/NCBI
27	Jabłońska-Trypuć A, Matejczyk M and Rosochacki S: Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem. 31:177–183. 2016. View Article : Google Scholar : PubMed/NCBI
28	Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, Ramirez-Acuña JM, Perez-Romero BA, Guerrero-Rodriguez JF, Martinez-Avila N and Martinez-Fierro ML: The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci. 21:97392020. View Article : Google Scholar : PubMed/NCBI
29	Dudley AC and Griffioen AW: Pathological angiogenesis: Mechanisms and therapeutic strategies. Angiogenesis. 26:313–347. 2023. View Article : Google Scholar : PubMed/NCBI
30	Rajabi M and Mousa SA: The role of angiogenesis in cancer treatment. Biomedicines. 5:342017. View Article : Google Scholar : PubMed/NCBI
31	Majidpoor J and Mortezaee K: Angiogenesis as a hallmark of solid tumors-clinical perspectives. Cell Oncol (Dordr). 44:715–737. 2021. View Article : Google Scholar : PubMed/NCBI
32	Zhou Q, Chen X, Chen Q and Hao L: Analysis of angiogenesis-related signatures in the tumor immune microenvironment and identification of clinical prognostic regulators in lung adenocarcinoma. Crit Rev Eukaryot Gene Expr. 33:1–16. 2023. View Article : Google Scholar : PubMed/NCBI
33	Onn A, Bar J and Herbst RS: Angiogenesis inhibition and lung-cancer therapy. Lancet Oncol. 15:124–125. 2014. View Article : Google Scholar : PubMed/NCBI
34	Melincovici CS, Boşca AB, Şuşman S, Mărginean M, Mihu C, Istrate M, Moldovan IM, Roman AL and Mihu CM: Vascular endothelial growth factor (VEGF)-key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 59:455–467. 2018.PubMed/NCBI
35	Chen H, Cong Q, Du Z, Du Z, Liao W, Zhang L, Yao Y and Ding K: Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling. Cancer Lett. 382:44–52. 2016. View Article : Google Scholar : PubMed/NCBI
36	Cheng SS, Yang GJ, Wang W, Leung CH and Ma DL: The design and development of covalent protein-protein inter-action inhibitors for cancer treatment. J Hematol Oncol. 13:262020. View Article : Google Scholar : PubMed/NCBI
37	Yang D, Hu Z, Xu J, Tang Y, Wang Y, Cai Q and Zhu Z: MiR-760 enhances sensitivity of pancreatic cancer cells to gemcitabine through modulating Integrin β1. Biosci Rep. 39:BSR201923582019. View Article : Google Scholar : PubMed/NCBI
38	El Messaoudi-Aubert S, Nicholls J, Maertens GN, Brookes S, Bernstein E and Peters G: Role for the MOV10 RNA helicase in polycomb-mediated repression of the INK4a tumor suppressor. Nat Struct Mol Biol. 17:862–868. 2010. View Article : Google Scholar : PubMed/NCBI
39	He Q, Zhao L, Liu X, Zheng J, Liu Y, Liu L, Ma J, Cai H, Li Z and Xue Y: MOV10 binding circ-DICER1 regulates the angiogenesis of glioma via miR-103a-3p/miR-382-5p mediated ZIC4 expression change. J Exp Clin Cancer Res. 38:92019. View Article : Google Scholar : PubMed/NCBI
40	Li W, Deng X and Chen J: RNA-binding proteins in regulating mRNA stability and translation: roles and mechanisms in cancer. Semin Cancer Biol. 86:664–677. 2022. View Article : Google Scholar : PubMed/NCBI
41	Shiota T, Li TC, Nishimura Y, Yoshizaki S, Sugiyama R, Shimojima M, Saijo M, Shimizu H, Suzuki R, Wakita T, et al: Integrin α3 is involved in non-enveloped hepatitis E virus infection. Virology. 536:119–124. 2019. View Article : Google Scholar : PubMed/NCBI
42	Hamidi H and Ivaska J: Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer. 18:533–548. 2018. View Article : Google Scholar : PubMed/NCBI
43	Cheng S, Li M, Zheng W, Li C, Hao Z, Dai Y, Wang J, Zhuo J and Zhang L: ING3 inhibits the malignant progression of lung adenocarcinoma by negatively regulating ITGB4 expression to inactivate Src/FAK signaling. Cell Signal. 117:1110662024. View Article : Google Scholar : PubMed/NCBI
44	Moye AL, Dost AF, Ietswaart R, Sengupta S, Ya V, Aluya C, Fahey CG, Louie SM, Paschini M and Kim CF: Early-stage lung cancer is driven by a transitional cell state dependent on a KRAS-ITGA3-SRC axis. EMBO J. 43:2843–2861. 2024. View Article : Google Scholar : PubMed/NCBI
45	Tang XR, Wen X, He QM, Li YQ, Ren XY, Yang XJ, Zhang J, Wang YQ, Ma J and Liu N: MicroRNA-101 inhibits invasion and angiogenesis through targeting ITGA3 and its systemic delivery inhibits lung metastasis in nasopharyngeal carcinoma. Cell Death Dis. 8:e25662017. View Article : Google Scholar : PubMed/NCBI